CEA-targeted ISAC

CEA-targeted ISAC (Immune-Stimulating Antibody Conjugate) is a therapeutic candidate being developed by Bolt Biotherapeutics using its proprietary Boltbody platform. The molecule consists of a monoclonal antibody specific for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5/CEA) conjugated to a next-generation Toll-like receptor 7/8 (TLR7/8) agonist payload. This approach is designed to convert "cold" tumors into "hot" tumors by activating the innate immune system within the tumor microenvironment. Upon binding to CEA-expressing tumor cells, the ISAC promotes antibody-dependent cellular phagocytosis (ADCP) and activates tumor-infiltrating myeloid cells, such as macrophages and dendritic cells. This activation leads to the production of pro-inflammatory cytokines (e.g., IL-12, IFNγ, TNFα) and the subsequent priming of a durable, systemic T-cell-mediated anti-tumor response. Preclinical studies in colorectal, pancreatic, and lung cancer models have demonstrated significant tumor growth inhibition, complete regressions, and the development of immunological memory.

Brand names

Boltbody

Other names

CEACAM5-targeted ISACCEACAM-5-targeted ISACCEACAM 5-targeted ISACCEA-targeted Boltbody ISACCEA-targeted immune-stimulating antibody conjugate